Aug 21, 2019 7:00am EDT Tonix Pharmaceuticals and Massachusetts General Hospital Enter into Research Collaboration to Develop Tonix’s Third Generation Anti-CD154 Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Organ Transplant Rejection
Aug 20, 2019 7:00am EDT Tonix Pharmaceuticals Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the Treatment of PTSD
Aug 12, 2019 8:00am EDT Tonix Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights
Jul 25, 2019 7:00am EDT Tonix Pharmaceuticals Announces Issuance of U.S. Patent for the Composition and Formulation of TNX-102 SL
Jun 13, 2019 7:00am EDT Tonix Pharmaceuticals Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL
May 30, 2019 8:00am EDT Tonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
